Denali Therapeutics
Denali Therapeutics Inc is an American clinical-stage biopharmaceutical company developing therapies for neurodegenerative and lysosomal storage diseases. The company utilizes its proprietary Transport Vehicle technology platform to engineer therapeutic molecules that cross the blood-brain barrier for CNS targets. Principal revenues are generated through strategic research collaborations, licensing agreements, and milestone payments from global biopharmaceutical partners. Core end markets serve neurology clinical centers, lysosomal storage disease clinics, and specialized rare disease treatment facilities. Denali Therapeutics holds a pioneering position in brain delivery technology and neurodegenerative disease drug development. The company is headquartered in South San Francisco, California, and its common stock trades on the Nasdaq Global Select Market.
8 of the funds FundTelligence covers report a position in Denali Therapeutics.
- Legal name
- Denali Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 8
- Exposure themes
- Ageing & Longevity, Age-Related Disease, Neurodegeneration
Funds holding Denali Therapeutics
- Lannebo Global Growth — Lannebo · 1.7 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 0.65 % (full portfolio disclosed, June 2026)
- BNP Health Care Innovators — BNP Paribas · 0.63 % (full portfolio disclosed, June 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.32 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.2 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.03 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)